Good morning :)
Switch to
Place Order

SeQuent Scientific Ltd

SEQUENT
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,234 cr, stock is ranked 760
High RiskStock is 3.09x as volatile as Nifty
90.450.56% (+0.50)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,234 cr, stock is ranked 760
High RiskStock is 3.09x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
54.173.02
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.924.360.88%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

SeQuent Scientific Limited is an India-based integrated pharmaceutical company. The Company operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The Company through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+1.05+1.19+1.37+1.42+0.05+0.07+0.10+0.04
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 21, 2022

Sequent Scientific Limited has informed the Exchange about related party transactions for the half year ended September 30, 2022. | Download

Sequent Scientific Limited has informed the Exchange about related party transactions for the half year ended September 30, 2022. | Download

Reply to Clarification Sought 
Announced OnNov 14, 2022

The Exchange had sought clarification from Sequent Scientific Limited with respect to announcement dated 09-May-2022 informing about Fire incident in wholly owned subsidiary Unit at Ramky Pharma City SEZ JNPC, Visakhapatnam. On the basis of aforesaid announcement, the Company was required to provide/clarify the following: Disruption of operations due to natural calamity, force majeure or events such as strikes, lockouts etc (At the time of occurrence) 1. Expected quantum of loss/damage caused; 2. Whether loss/damage covered by insurance or not including amount; 3. Estimated impact on the production/operations in case of strikes/lock outs; Disruption of operations due to natural calamity, force majeure or events such as strikes, lockouts etc (Regularly, till complete normalcy is restored) 1. Insurance amount claimed and realized by the listed entity for the loss/damage; 2. The actual amount of damage caused due to the natural calamity or other force majeure events; 3. Details of steps taken to restore normalcy and the impact of the natural calamity/other force majeure events on production or service, financials of the entity The response of the company is attached. | Download

The Exchange had sought clarification from Sequent Scientific Limited with respect to announcement dated 09-May-2022 informing about Fire incident in wholly owned subsidiary Unit at Ramky Pharma City SEZ JNPC, Visakhapatnam. On the basis of aforesaid announcement, the Company was required to provide/clarify the following: Disruption of operations due to natural calamity, force majeure or events such as strikes, lockouts etc (At the time of occurrence) 1. Expected quantum of loss/damage caused; 2. Whether loss/damage covered by insurance or not including amount; 3. Estimated impact on the production/operations in case of strikes/lock outs; Disruption of operations due to natural calamity, force majeure or events such as strikes, lockouts etc (Regularly, till complete normalcy is restored) 1. Insurance amount claimed and realized by the listed entity for the loss/damage; 2. The actual amount of damage caused due to the natural calamity or other force majeure events; 3. Details of steps taken to restore normalcy and the impact of the natural calamity/other force majeure events on production or service, financials of the entity The response of the company is attached. | Download

Cash Dividend 
Ex. DateSep 8, 2021

Final • Div/Share: ₹ 0.5

See all events